Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
OMAHA-004
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT06136650 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on OMAHA-004 (opevesostat in metastatic castration-resistant prostate cancer post one NHA) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OMAHA-004 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
- Interventions
- Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone; Abiraterone acetate; Prednisone acetate; Enzalutamide
- Arms
- Daily Corticosteroids + Opevesostat · Experimental
- Alternative Next-Generation Hormonal Agent (NHA) · Active comparator
- Enrollment
- 1,314 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 18, 2023
- Primary completion
- May 10, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06136650 · updated Oct 20, 2026
Publications
linked from the registry- Yu EY, Gratzke C, Burotto M, Zhang AY, Levesque E, Ortega F, Peer A, Vile D, Chen ZH, Song Y, Schloss C, Todoric J, Garratt C, Poehlein C, Antonarakis ES, Fizazi K. Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. Future Oncol. 2026 Mar;22(7):765-772. doi: 10.1080/14796694.2025.2595914. Epub 2026 Feb 23. PubMed 41732008